Rusan Pharma to invest ₹200 crore in Kandla for addiction treatment market push

Rusan Pharma plans to invest ₹200 crore to expand manufacturing capacity at its Kandla facility in Gujarat, targeting a projected ₹20,000-25,000 crore addiction treatment market in India over the next three to four years. The company, which has worked in addiction treatment since 1994, distributes products through government programmes and 240 private rehabilitation clinics, covering drug, alcohol, and tobacco addiction. It also expects critical pain management to drive growth, citing a significant gap between India's morphine need of 36 MT and current consumption of around 480 kg. Rusan aims to increase group business to ₹1,000 crore by 2027-28 from about ₹450 crore currently, with 70% of turnover from narcotic and psychotropic products. It also operates in the UK, EU, US, and South Africa, while citing regulatory delays under the NDPS Act as a constraint.